This post was just published on ZYX Buy Change Alert. Only 62 days ago our call was to buy ALIOY on a potential buyout. Average price is $45.57. This is the 121st buyout of our portfolio companies. Over the years, the long-time subscribers to The Arora Report have generated substantial wealth from so many
Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, with high confidence, that it’s time to sell stocks. At the same time, bullish gurus are saying just the opposite. So who’s right? Let’s explore the answer. First, we need
Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. It was health care. And shares of U.S. pharmaceutical companies promptly fell, dropping by an average range of about 3% to 5%. “We’ve got to get our drug industry back,”
I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one must put prudence over popularity. Human nature as it is, investors often find it difficult to take unpopular actions. My motivation in writing this column is to nudge you
Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he will replace Obamacare with something better. In his speeches, Trump outlined certain key points
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers. ) JAPAN STUNS WITH NEGATIVE INTEREST RATES, RUSSIA CLARIFIES ON OIL, AND GDP RELEASE January 29, 2016 This is what you need to know today. Japan
One of the rumored suitors of SNN has been MDT. MDT just bought COV and is now likely out of the race to buy SNN. There are still other suitors of SNN such as SYK and JNJ, but the stock is likely to drift lower unless an immediate bid appears.
It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec. Novartis had filed a plea with the Supreme
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers.) THE RALLY IS LONG IN THE TOOTH January 25, 2013 The stock market rally is long in the tooth. Our long time subscribers know
Nine jurors in the Federal Court of the Northern District of California, handed Apple a big victory against Samsung, awarding Apple $1.05 billion in damages, finding all seven of Apple’s patents valid, finding Samsung infringed six of Apple’s patents, and finding Apple not to have infringed any of Samsung’s five patents. The